IRIS
COSTANTINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.590
AS - Asia 2.562
EU - Europa 2.547
SA - Sud America 601
Continente sconosciuto - Info sul continente non disponibili 203
AF - Africa 114
OC - Oceania 29
Totale 11.646
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.483
SG - Singapore 825
IT - Italia 579
CN - Cina 530
VN - Vietnam 518
BR - Brasile 460
RU - Federazione Russa 407
UA - Ucraina 312
SE - Svezia 251
HK - Hong Kong 233
DE - Germania 205
IE - Irlanda 184
FR - Francia 170
GB - Regno Unito 105
BD - Bangladesh 101
DK - Danimarca 96
FI - Finlandia 90
TR - Turchia 77
IN - India 61
KR - Corea 56
AR - Argentina 53
NL - Olanda 53
CA - Canada 48
CI - Costa d'Avorio 39
MX - Messico 32
AU - Australia 27
CO - Colombia 26
EC - Ecuador 24
JP - Giappone 22
AT - Austria 21
IQ - Iraq 21
ID - Indonesia 17
ZA - Sudafrica 17
PL - Polonia 15
MA - Marocco 14
VE - Venezuela 13
EG - Egitto 12
BE - Belgio 11
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
ES - Italia 10
PK - Pakistan 10
UZ - Uzbekistan 10
KE - Kenya 9
TN - Tunisia 8
CL - Cile 7
MY - Malesia 7
PH - Filippine 7
CH - Svizzera 6
JM - Giamaica 6
JO - Giordania 6
KZ - Kazakistan 6
NP - Nepal 6
RO - Romania 6
SA - Arabia Saudita 6
TH - Thailandia 6
AL - Albania 5
AZ - Azerbaigian 5
DZ - Algeria 5
IL - Israele 5
LT - Lituania 5
DO - Repubblica Dominicana 4
BG - Bulgaria 3
CR - Costa Rica 3
GT - Guatemala 3
SV - El Salvador 3
UY - Uruguay 3
AM - Armenia 2
BO - Bolivia 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
KW - Kuwait 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TW - Taiwan 2
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BS - Bahamas 1
CD - Congo 1
CG - Congo 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EU - Europa 1
FJ - Figi 1
GY - Guiana 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LV - Lettonia 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
Totale 11.435
Salva come PNG Salva come JPEG
Città #
Ashburn 929
Singapore 470
Dallas 454
Chandler 376
Jacksonville 319
Fairfield 247
San Jose 245
Council Bluffs 227
Hong Kong 227
Boardman 187
Dublin 181
Ho Chi Minh City 170
New York 146
Wilmington 144
Beijing 131
Des Moines 128
Woodbridge 114
Hanoi 107
Seattle 102
Los Angeles 100
Ann Arbor 85
Houston 85
Lauterbourg 82
The Dalles 74
San Mateo 73
Princeton 72
Lawrence 71
Rome 69
Redmond 58
Moscow 55
Hefei 53
Milan 52
Cambridge 50
Chicago 41
Centro 40
San Diego 40
Abidjan 39
Orem 38
São Paulo 37
Da Nang 36
Ancona 33
Munich 32
Santa Clara 32
Buffalo 30
Helsinki 29
London 24
Haiphong 23
Denver 22
Guangzhou 21
Marche 21
Phoenix 21
Chennai 17
Rio de Janeiro 17
Turin 17
Atlanta 16
Turku 16
Florence 15
Melbourne 15
Norwalk 14
San Francisco 14
Shanghai 14
Tokyo 14
Biên Hòa 13
Amsterdam 12
Charlotte 12
Guayaquil 12
Istia D'ombrone 12
Johannesburg 12
Montreal 12
Warsaw 12
Washington 12
Wuhan 12
Bogotá 11
Brooklyn 11
Brussels 11
Columbus 11
Frankfurt am Main 11
Paris 10
Salt Lake City 10
Tashkent 10
Boston 9
Brookline 9
Civitanova Marche 9
Dhaka 9
Hải Dương 9
Istanbul 9
Nuremberg 9
Porto 9
Quanzhou 9
Toronto 9
Belo Horizonte 8
Buenos Aires 8
Chiaravalle 8
Elk Grove Village 8
Kingscliff 8
Miami 8
Miano 8
Bologna 7
Bến Tre 7
Genoa 7
Totale 6.984
Salva come PNG Salva come JPEG
Nome #
Specific Anti-Nuclear Antibodies, Clinical Features and Outcome Following Treatment with Nilotinib In Patients with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions 314
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 225
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 192
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 188
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. 187
Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT 183
A new method to assess the viability of collected CD34+ cells before reinfusion: a prospective study in 50 autotransplanted patients. 181
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 179
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals 179
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 178
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 174
Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. 174
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 170
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 168
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 167
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 167
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 151
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. 149
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV. 149
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 145
Activated switched memory B cell clusters in chronic spontaneous urticaria are increased in subjects with long disease duration and relapse upon omalizumab discontinuation: Results of the IL-10-OMZ study 144
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella 141
OC-34 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤50 copies/mL 140
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 140
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. 138
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. 137
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 137
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 134
OC-43 ‘U=U impossibile sbagliare’ awareness campaign: impact assessment among PLWH 133
Effects of cryopreservation on lymphocyte immunophenotype and function 132
CROI 2013: le ricadute per la pratica clinica. 131
Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens. 129
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 128
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 125
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 125
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL. 124
PROGETTO E-PROs: COSTRUZIONE DI UNA PIATTAFORMA DIGITALE PER LA GESTIONE DI STRUMENTI CENTRATI SUL PAZIENTE NELLA PRATICA CLINICA (The E-PROs Project: creation of a digital platform to manage patient-oriented tools in clinical practice). 123
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients 122
P131 Anlaids community-based HIV screening as a tool to improve HIV diagnosis among asymptomatic individuals 118
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 118
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 118
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 118
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report 118
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 117
OC52 Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) as first-line therapy and as switch strategy in virologically suppressed persons with HIV up to 192-weeks: data from the ICONA-BIC Study 114
SC6 Promoting hepatitis and HIV screening in high prevalence populations: the ‘test in the city’ project 114
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. 114
Humoral and cellular immunity after mRNA COVID-19 vaccine in psoriatic patients on biological or immunosuppressive therapy: a real-life experience 113
Do we still need CD4 T cell count? 112
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 112
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. 112
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. 110
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 109
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 109
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 109
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV 107
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 107
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. 107
P128 The role of ancona checkpoint in counseling and facilitating PrEP access through tele-visits 105
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 105
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 105
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 103
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 102
Polyclonal serum-free light chains elevation in HIV-infected patients. 102
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 101
Diagnostica immunologica. 100
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. 100
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 100
Lo studio fenotipico di linfociti e altre cellule mononucleate. 97
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 96
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. 96
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 94
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI 94
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 93
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 92
PRIMARY BILIARY CHOLANGITIS CASE- FINDING: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY ON PATIENTS WITH INCIDENTAL FINDING OF ANTI- MITOCHONDRIAL ANTIBODIES. 91
HIV among adolescents and young adults in Italy: focus on epidemiological, viro-immunological and treatment characteristics of 689 18-24 year old subjects enrolled in the ICONA Cohort. 89
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 87
Switch a raltegravir in un paziente con carcinoma a cellule di Merkel e sarcoma di Kaposi. 87
Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort 85
La ricerca degli anticorpi anti-nucleo non è sempre di facile interpretazione 85
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 83
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 82
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 82
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 80
La tollerabilità della terapia antiretrovirale come mezzo per la gestione a lungo termine di pazienti complessi: un caso clinico. 80
Il paziente adulto con immunodeficienza. 79
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 75
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of post-COVID-19 condition in vulnerable populations 73
Infezione da HIV-1. 70
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 69
L’immunoricostituzione, un paesaggio dai mutevoli confini 66
Management of vaccinations in patients with non‐Hodgkin lymphoma 60
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 57
La riduzione delle interazioni farmacologiche come mezzo per aumentare l’aderenza alla terapia antiretrovirale e garantirne la durability. 55
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 33
HIV infection among adolescents and young adults in Italy: Epidemiology, viro-immunological and treatment outcomes 32
Self-reported wellbeing and integration levels of migrants with HIV in Italy: a cross-sectional analysis fromthe ICONA cohort 32
Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC study 29
Did the COVID-19 pandemic shift the landscape of late HIV diagnosis? 15
Totale 11.620
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.979
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.979
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022548 0 129 12 34 8 31 30 52 43 48 58 103
2022/20231.153 107 121 75 118 79 230 0 61 277 4 50 31
2023/2024656 105 11 31 85 133 125 18 17 12 13 15 91
2024/20251.541 198 107 56 17 22 60 104 53 418 149 126 231
2025/20265.259 393 387 449 563 467 273 742 455 393 466 455 216
2026/2027358 251 107 0 0 0 0 0 0 0 0 0 0
Totale 11.646